Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

On January 29, 2026 Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, reported that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin in patients with peritoneal carcinomatosis from ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites have now been opened, and the first patient has been enrolled at one of these newly activated sites.

"The process of opening new clinical sites involves extensive regulatory reviews, contracting, and site-readiness work. We are therefore pleased to see both the successful activation of additional sites and the enrollment of the first patient at a newly onboarded site," said Kari Myren, Chief Medical Officer at Oncoinvent.

The Phase 2 trial (Clinicaltrial.gov: NCT06504147) is a randomized controlled trial assessing the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival (PFS) between patients who receive Radspherin after complete surgical resection following pre-operative chemotherapy, and patients receiving pre-operative chemotherapy and surgery alone.

The study will recruit patients at a total of 11 sites across Norway (1), Spain (5), Belgium (1), the United Kingdom (2), the United States (1), and Italy (1). Positive Phase 1/2a data from the safety interim analysis demonstrated that Radspherin was well tolerated with no dose-limiting toxicity observed at the recommended dose of 7MBq.

(Press release, Oncoinvent, JAN 29, 2026, https://www.oncoinvent.com/press-release/four-additional-sites-open-for-recruitment-in-oncoinvents-phase-2-trial/ [SID1234662334])